Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.
CTCS
NSCLC
PD-L1
ctDNA
exosomes
immunotherapy
miRNAs
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Apr 2021
09 Apr 2021
Historique:
received:
17
02
2021
revised:
02
04
2021
accepted:
03
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death (PD)-1 protein and its ligand, PD-L1, and cytotoxic T-lymphocyte-associated antigen (CTLA)-4, have revolutionized the management of patients with advanced non-small cell lung cancer (NSCLC). Unfortunately, only a small portion of NSCLC patients respond to these agents. Furthermore, although immunotherapy is usually well tolerated, some patients experience severe immune-related adverse events (irAEs). Liquid biopsy is a non-invasive diagnostic procedure involving the isolation of circulating biomarkers, such as circulating tumor cells (CTC), cell-free DNA (cfDNA), and microRNAs (miRNAs). Thanks to recent advances in technologies, such as next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR), liquid biopsy has become a useful tool to provide baseline information on the tumor, and to monitor response to treatments. This review highlights the potential role of liquid biomarkers in the selection of NSCLC patients who could respond to immunotherapy, and in the identification of patients who are most likely to experience irAEs, in order to guide improvements in care.
Identifiants
pubmed: 33918661
pii: cancers13081794
doi: 10.3390/cancers13081794
pmc: PMC8070633
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Italian Ministry of Health
ID : CO-2016-3; 02361470
Références
Acta Oncol. 2018 Sep;57(9):1225-1231
pubmed: 29683761
Lung Cancer. 2018 Dec;126:1-8
pubmed: 30527172
Nat Rev Clin Oncol. 2018 Oct;15(10):639-650
pubmed: 30050094
Lung Cancer. 2018 Jun;120:108-112
pubmed: 29748004
Front Immunol. 2020 Feb 07;11:125
pubmed: 32117275
Clin Cancer Res. 2018 Dec 15;24(24):6212-6222
pubmed: 30093454
Lung Cancer. 2019 Jun;132:107-113
pubmed: 31097082
Int J Mol Sci. 2017 May 11;18(5):
pubmed: 28492516
Cancer. 2015 Jan 1;121(1):139-49
pubmed: 25241991
Oncotarget. 2017 Dec 14;8(69):114268-114280
pubmed: 29371985
Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):392-7
pubmed: 27333219
Int J Mol Sci. 2019 May 30;20(11):
pubmed: 31151303
Drug Discov Today. 2017 Jun;22(6):927-936
pubmed: 28288782
JAMA Oncol. 2019 May 1;5(5):696-702
pubmed: 30816954
Dev Biol. 2007 Feb 1;302(1):1-12
pubmed: 16989803
Front Oncol. 2020 Jun 23;10:654
pubmed: 32656072
J Clin Med. 2019 Jul 10;8(7):
pubmed: 31295929
Transl Oncol. 2020 Dec;13(12):100865
pubmed: 32920330
Clin Lung Cancer. 2018 Sep;19(5):410-417.e1
pubmed: 29859759
Curr Opin Oncol. 2016 Mar;28(2):130-4
pubmed: 26730486
Ther Adv Med Oncol. 2018 Apr 07;10:1758835918768238
pubmed: 29662549
Clin Lung Cancer. 2019 Jul;20(4):270-277.e1
pubmed: 31005568
Cancers (Basel). 2020 Feb 19;12(2):
pubmed: 32092983
Adv Ther. 2020 Mar;37(3):1145-1155
pubmed: 32002809
Cancer Med. 2018 Dec;7(12):5910-5919
pubmed: 30565869
Clin Cancer Res. 2018 Apr 15;24(8):1872-1880
pubmed: 29330207
J Immunother Cancer. 2020 Jan;8(1):
pubmed: 31959728
Ann Oncol. 2019 Sep 1;30(9):1448-1459
pubmed: 31228184
Oncotarget. 2017 Oct 24;8(60):101994-102005
pubmed: 29254220
Immunotherapy. 2016 Sep;8(9):1011-9
pubmed: 27485075
Front Immunol. 2019 Jun 04;10:1242
pubmed: 31214193
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
Clin Cancer Res. 2017 Sep 1;23(17):5101-5111
pubmed: 28539465
Sci Rep. 2020 Jun 3;10(1):9050
pubmed: 32493990
J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485
pubmed: 30506406
Curr Oncol Rep. 2020 May 16;22(6):56
pubmed: 32415399
Genomics. 2020 Mar;112(2):2063-2071
pubmed: 31786291
Expert Opin Drug Metab Toxicol. 2020 Feb;16(2):87-96
pubmed: 31978315
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Cancers (Basel). 2020 Feb 27;12(3):
pubmed: 32120803
Mol Oncol. 2016 Mar;10(3):395-407
pubmed: 26795350
Br J Cancer. 2018 Mar 20;118(6):820-824
pubmed: 29509748
Ther Adv Med Oncol. 2020 Oct 31;12:1758835920952994
pubmed: 33193825
Ann Biol Clin (Paris). 2017 Dec 1;75(6):619-630
pubmed: 29192597
Medicine (Baltimore). 2017 Feb;96(7):e6102
pubmed: 28207525
J Transl Med. 2019 Mar 8;17(1):74
pubmed: 30849967
Curr Drug Targets. 2015;16(1):47-59
pubmed: 25495923
Lung Cancer. 2020 Oct;148:1-11
pubmed: 32768804
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1139-1145
pubmed: 28446544
Oncotarget. 2016 Aug 30;7(35):56233-56240
pubmed: 27191652
Drug Discov Today. 2014 Oct;19(10):1671-6
pubmed: 24928031
J Thorac Dis. 2017 Nov;9(11):4300-4304
pubmed: 29268496
J Immunother Cancer. 2019 Jul 10;7(1):173
pubmed: 31291995
Cancers (Basel). 2019 Dec 05;11(12):
pubmed: 31817541
Lung Cancer. 2019 Nov;137:1-6
pubmed: 31518912
Sci Rep. 2018 Feb 7;8(1):2592
pubmed: 29416054
Clin Lung Cancer. 2009 Jan;10(1):42-6
pubmed: 19289371
J Thorac Oncol. 2017 Jan;12(1):43-53
pubmed: 27543256
Front Oncol. 2014 Sep 04;4:242
pubmed: 25237652
Sensors (Basel). 2014 Mar 10;14(3):4856-75
pubmed: 24618729
Cancer Res. 2019 Mar 15;79(6):1214-1225
pubmed: 30541742
Nat Rev Clin Oncol. 2021 May;18(5):297-312
pubmed: 33473219
Oncoimmunology. 2018 Apr 20;7(8):e1452581
pubmed: 30221046
Expert Opin Drug Saf. 2017 May;16(5):573-585
pubmed: 28351171
Nat Rev Clin Oncol. 2017 Sep;14(9):531-548
pubmed: 28252003
Sci Rep. 2016 Aug 24;6:31726
pubmed: 27553175
Drug Discov Today. 2017 Aug;22(8):1266-1273
pubmed: 28600190
Nat Med. 2008 Sep;14(9):985-90
pubmed: 18670422
Ther Clin Risk Manag. 2017 Oct 11;13:1363-1374
pubmed: 29066904
Crit Rev Oncol Hematol. 2019 Nov;143:148-152
pubmed: 31675543
Ann Oncol. 2018 Jan 1;29(1):193-199
pubmed: 29361135
Oncologist. 2019 Aug;24(8):1128-1136
pubmed: 31015312
J Thorac Oncol. 2019 Mar;14(3):494-502
pubmed: 30503891
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998
pubmed: 28446615
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
Eur J Cancer. 2017 Nov;86:349-357
pubmed: 29078173
Cancers (Basel). 2019 Dec 19;12(1):
pubmed: 31861557